Fig 1: KCTD15 silencing increase the Doxorubicin and Trastuzumab sensitivity of SKBR3 cells. (A) MTT assay of untreated SKBR3ctrl and SKBR3KCTD15- (filled bars) and doxorubicin treated SKBR3ctrl and SKBR3KCTD15- (squared bars) at 2 and 5 µM for 16h. * = p-value < 0.05. (B) MTT assay of Trastuzumab treated SKBR3ctrl (orange bar) and SKBR3KCTD15- (orange square bar) in comparison with the untreated control cells (SKBR3ctrl, Black bar and SKBR3KCTD15-, Red bar). * = p-value < 0.05, Mann–Whitney t-test. n.s. = not significative. Error bars represent SD of three independent experiments.
Fig 2: KCTD15 expression in breast cancer tissues and cell lines. (A) Bar-plots display fluorescence intensity (in terms of median of fluorescence and SEM) of KCTD15 in MCF10 (light green), MDA-MB-231 (pink), MCF7 (blue), BT-474 (orange), SKBR3 (light blue), MDA-MB-361 (black), MDA-MB-453 (light brown) and T47D (green). The error bar represents SEM. **** = p < 0.0001, * = p < 0.05. Mann Whitney T-test. Panel (B) shows KCTD15 expression using WB. Numbers represent protein marker expressed in kDa. Western blot is representative of three independent experiments with similar results. Panel (C) displayed KCTD15 expression level in breast tissues by IHC analysis: 4 Luminal A (score 2), 4 Luminal B (score 2), 4 HER2 enriched (score 3), and 4 healthy subtypes (score 0). Magnification 40×. Scale bars 50 µm.
Fig 3: CRISPR/CAS9 KCTD15 silencing reduces SKBR3 growth. (A) Cell proliferation at 24, 48 and 72 h of SKBR3 control (black line) and SKBR3KCTD15- (red line). Cell growth was expressed as number of cells/µL. Error bars represent the SD of three independent experiments. * = p-value < 0.05 (B) MTT assay of SKBR3ctrl (Black bar) and SKBR3KCTD15- (red bar) after 72 h of growth. * = p-value < 0.05, ** = p-value < 0.01, Mann–Whitney t-test. Error bars represent the SD of six independent experiments. (C) Cyclins mRNA expression levels in SKBR3ctrl (black bar) and SKBR3KCTD15- (red bar). The relative expression was determined using the 2-?Ct method. Cyclins relative expression is shown as mean +/- SD of two technical independent experiments. * = p-value < 0.05, Mann–Whitney t-test.
Fig 4: KCTD15 mRNA predicts worst survival in breast cancer subtypes. Kaplan–Meier plots generated from GEPIA show Overall Survival in breast cancer subtypes with high and low levels of KCTD15 mRNA. (A) Triple Negative patients. (B) Luminal B patients. (C) Luminal A patients. (D) HER2+ patients. Log-rank, Chi-squared test for statistical analysis.
Fig 5: KCTD15 silencing influences the SKBR3 migration. SKBR3ctrl and SKBR3KCTD15- migration was determined using trans-well chamber by Crystal violet (A) and DAPI (B) staining of migrated cells. ** = p < 0.01 Mann–Whitney T-test. Crystal violet signal (590 nm) is reported as mean +/- SD of three technical independent experiments. For DAPI staining, the magnification reported is 20×. Scale bars 200 µm.
Supplier Page from Abcam for Anti-KCTD15 antibody